Artelo Biosciences ( (ARTL) ) has released its Q4 earnings. Here is a breakdown of the information Artelo Biosciences presented to its investors.
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways to address unmet needs in cancer, pain, dermatologic, and neurological conditions.
The company recently released its fiscal 2024 year-end financial results and provided a business update, highlighting significant progress in its clinical programs and financial performance.
Key developments include the advancement of ART26.12, a Fatty Acid Binding Protein inhibitor, with its Phase I study expected to conclude in Q2 2025. ART27.13 is progressing in the Phase 2 CAReS trial, targeting cancer anorexia, with initial data anticipated by the end of Q2 2025. Additionally, ART12.11 is set to begin human studies in the second half of 2025, offering a novel approach to treating anxiety and depression. Financially, Artelo reported a net loss of $9.8 million for 2024, slightly higher than the previous year, with research and development expenses increasing to $6.0 million.
Looking ahead, Artelo Biosciences is poised to achieve important clinical milestones in 2025, with management expressing optimism about the potential of their innovative therapies to address significant unmet medical needs.